BrightInsight has raised $13 million from Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners to accelerate its AI-enabled medication persistence and adherence platform. The funding will advance end-to-end AI capabilities such as churn prediction, expand a disease-specific partner ecosystem, and extend support to additional stakeholders including caregivers and nurse educators. It also aims to rapidly scale marquee deployments, including a patient app developed with Sanofi and Regeneron, across multiple diseases and geographies.
The strategic signal is less about the size of the round and more about where pharma is placing its next bet. After a cycle of digital health exuberance followed by consolidation, life sciences sponsors are shifting from standalone digital therapeutics to therapy-tethered companion tools that measurably move persistence curves. BrightInsight is positioning squarely in that gap, offering a compliant, configurable platform that can be embedded in patient support programs, software as a medical device modules, and brand ecosystems without asking pharma to stitch together point solutions.
The timing matters. Adherence in chronic disease remains stubbornly low, driving avoidable clinical events and spend, just as payers tighten access and push for proof that high-cost therapies deliver outcomes in the real world. If AI can identify early churn signals and trigger personalized interventions, commercial teams gain a lever to protect lifetime value and medical teams gain a path to generate pragmatic evidence that adherence support changes trajectories. Reported participation and one-year retention rates that materially exceed typical patient app benchmarks, if reproduced at portfolio scale and in diverse populations, would reset expectations for what patient support should deliver.
This move sits at the intersection of several industry currents: the retrenchment of pure-play digital therapeutics, the rise of omnichannel patient support anchored to flagship brands, and the surge of AI applications that turn longitudinal engagement into actionable real-world data. It also raises governance questions Medical Affairs and regulatory teams will need to navigate. As predictive models inform dosing reminders, side-effect triage, or escalation to nurse educators, sponsors must determine when these features remain non-device support and when they edge into SaMD territory under FDA guidance and the EU AI Act. Data provenance, bias mitigation, and workflow integration with specialty pharmacies and EHRs will separate scalable platforms from pilots that never leave the brand team’s sandbox.
For commercial leaders, the near-term opportunity is practical: use adherence lift to de-risk launches, defend price in value dossiers, and unlock outcomes-based constructs with payers. Categories with heavy persistence drag—oral oncolytics, cardiometabolic combinations including GLP-1–based regimens, autoimmune biologics, and respiratory maintenance therapies—are likely early beneficiaries. For Medical Affairs, the ask is to convert engagement telemetry into credible, peer-reviewed RWE and field education that HCPs trust, while harmonizing with REMS, hub services, and nurse-led virtual care.
The next proof points will determine whether this is another incremental PSP upgrade or the backbone of enterprise-wide patient engagement. Watch for multi-brand, multi-country expansions with hard clinical and economic endpoints, payer co-sponsorship of adherence programs, and clear regulatory positioning of AI features. The open question for 2026: can platforms like BrightInsight deliver guaranteed, contractible persistence gains at scale—and will payers start requiring them as table stakes for high-cost therapies?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
